Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

10/9/24 8:30:59 AM ET

$ATXI

$FBIO

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ATXI alert in real time by email

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.

The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here.

About Avenue Therapeutics

Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA_A α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). For more information, visit www.avenuetx.com.

Contact:

Jaclyn Jaffe

Avenue Therapeutics, Inc.

(781) 652-4500

[email protected]

Get the next $ATXI alert in real time by email

Company	Date	Price Target	Rating	Analyst
Fortress Biotech Inc. $FBIO	3/15/2024	$10.00	Buy	ROTH MKM
Fortress Biotech Inc. $FBIO	8/4/2022	$6.00	Buy	Ladenburg Thalmann

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

Chat with this insight

Recent Analyst Ratings for $ATXI$FBIO

$ATXI$FBIO Press Releases

Fastest customizable press release news feed in the world

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

$ATXI$FBIO Financials

Live finance-specific insights

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

$ATXI$FBIO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Fortress Biotech Inc.

Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

SEC Form SC 13G/A filed by Avenue Therapeutics Inc. (Amendment)

$ATXI$FBIO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Kranzler Jay D sold $137 worth of shares (61 units at $2.24), decreasing direct ownership by 10% to 559 units (SEC Form 4)

Chief Financial Officer Jin David was granted 2,625 shares, increasing direct ownership by 1% to 240,893 units (SEC Form 4)

Director Kranzler Jay D bought $1,250 worth of shares (500 units at $2.50), increasing direct ownership by 417% to 620 units (SEC Form 4)

$ATXI$FBIO Leadership Updates

Live Leadership Updates

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

$ATXI$FBIO SEC Filings

Fortress Biotech Inc. filed SEC Form 8-K: Other Events

SEC Form 424B3 filed by Fortress Biotech Inc.

SEC Form EFFECT filed by Fortress Biotech Inc.

$ATXI$FBIO Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $24 Price Target

GC Cell And Checkpoint Therapeutics To Explore Combined Therapeutic Potential Of Cosibelimab

$ATXI$FBIO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Kranzler Jay D bought $1,250 worth of shares (500 units at $2.50), increasing direct ownership by 417% to 620 units (SEC Form 4)

PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

$ATXI$FBIO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM resumed coverage on Fortress Biotech with a new price target

Ladenburg Thalmann initiated coverage on Fortress Biotech with a new price target

Roth Capital reiterated coverage on Fortress Biotech with a new price target

Recent Analyst Ratings for
$ATXI
$FBIO

$ATXI
$FBIO
Press Releases

$ATXI
$FBIO
Financials

$ATXI
$FBIO
Large Ownership Changes

$ATXI
$FBIO
Insider Trading

$ATXI
$FBIO
Leadership Updates

$ATXI
$FBIO
SEC Filings

$ATXI
$FBIO
Market Insights

$ATXI
$FBIO
Insider Purchases

$ATXI
$FBIO
Analyst Ratings